ArticlePrecision clinical medicine2025
Clinical and genomic characteristics of HER2-ultralow breast cancer and implications for T-DXd therapy.
Article in Precision clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HER2-Low Breast Cancer: Biological Framework and Determinants of HER2 Instability.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The clinical benefit of T-DXd in advanced breast cancer with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-ultralow tumors in the DESTINY-Breast06 trial has drawn attention to this subtype. Methods: We re-evaluated 473 pathological specimens from 302 HER2-negative breast cancer patients in our next generation sequencing database, classifying HER2-negative status into HER2-ultralow, IHC 0 without membrane staining (MS-) and HER2-low. Clinicopathologic characteristics and genomic profiles were analyzed by HER2 status. Results: Overall, 35.5% of primary and 49.0% of metastatic HER2-IHC 0 tumors were reclassified as ultralow. Subtype analysis based on HR status showed no distinct clinicopathological characteristics in the HER2-ultralow subgroup. Upon metastasis, 40% of HER2-ultralow primary tumors converted to IHC 0 (MS-) and 46.7% to HER2-low. In the metastatic tumors, 60% of HER2-IHC 0 (MS-) and 50% of HER2-ultralow translated to other HER2 statuses in re-obtained samples. HER2-ultralow status was associated with worse disease-free survival than HER2-IHC 0 (MS-) and HER2-low status in HR-negative breast cancer, but no differences of overall survival were observed. The median progression-free survival for first-line chemotherapy was 7.2 months in HR+ HER2-low, 6.8 months in ultralow, and 8.8 months in IHC 0 (MS-) patients ( Conclusion: In conclusion, HER2-ultralow status is not associated with distinct clinicopathologic or genomic characteristics. HER2-IHC 0 (MS-) and ultralow statuses often coexist within the same patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.